期刊文献+

肿瘤切除和术后复发对乳腺癌患者血管生成平衡的影响 被引量:1

Effect of tumor surgery and postoperative relapse on angiogenesis balance in breast cancer
下载PDF
导出
摘要 目的观察乳腺癌患者血清血管内皮生长因子(VEGF)和内皮细胞抑制素(ES)浓度比值在手术前、后及复发时的变化,探讨肿瘤切除和术后复发对体内血管生成平衡的可能影响。方法分别采用竞争性酶联免疫试验和ELISA法测定5 9例乳腺癌患者手术前、后和复发时血清VEGF及ES水平,计算VEGF/ES比值,并与3 0例乳腺良性肿瘤和5 9例正常对照组比较。结果(1)手术前乳腺癌患者血清VEGF和ES水平与两对照组相比均显著增高(P<0.0 0 5),VEGF/ES比值为9.1;手术后3周时,血清VEGF水平明显下降,而ES仍保持在较高状态,VEGF/ES比值下降至3.3。(2)复发患者术后VEGF/ES比值与术前相比也有所下降(1 0.3 vs 7.4),但一旦疾病复发时VEGF水平又急剧上升,VEGF/ES比值升至1 4.2。多因素分析显示,术后VEGF/ES比值是影响乳腺癌患者复发转移率的一个独立因素。结论乳腺癌肿瘤切除可影响患者体内血清VEGF-ES间平衡,监测VEGF/ES比值对患者预后评估有一定的辅助意义。 Objective To observe the serum VEGF/ES ratios before and after operation and at clinical relapse in patients with breast cancer, and to discuss the potential effect of tumor surgery and postoperative relapse on the angiogenesis balance. Methods The serum VEGF and ES levels of 59 cases of breast cancer before and after operation and at clinical relapse were determined using competitive enzyme immunoassays and ELISA, respectively, and compared with the results of 30 cases of benign breast tumors and 59 cases of normal controls. Results ( 1 ) Preoperatively, the serum ES and VEGF levels of breast cancer patients were significantly elevated, as compared to the other 2 groups, and the VEGF/ES ratio was 9. 1. Postoperatively, at 3 weeks, VEGF level decreased significantly and ES remained at a high level. The VEGF/ES ratio was 3.3. (2)At the time of clinical relapse, serum VEGF level was followed by marked elevation, and the VEGF/ES ratio increased up to 14. 2. Multivariate analyses showed that the postoperative VEGF/ES ratio was an independent factor related to the postoperative recurrence of breast cancer. Conclusions Breast cancer surgery may affect the balance between serum VEGF and ES, and the determination of VEGF/ES ratio can have auxiliary value in the assessment of prognosis of breast cancer patients.
出处 《中国普通外科杂志》 CAS CSCD 2005年第9期672-675,共4页 China Journal of General Surgery
关键词 乳腺肿瘤/血液 血管内皮生长因子/血液 内皮细胞抑制素/血液 Breast Neoplasms/blood VEGF/blood ES/blood
  • 相关文献

参考文献10

  • 1Kuroi, Toi M. Circulating angiogenesis regulator in cancer patients[J]. Int J Biol Markers, 2001, 16(1) :5 -26.
  • 2.
  • 3Poon RT, Fan ST, Wong J. Clinical implication of circulating angiogenic factors in cancer patients [ J ] . J Clin Oncol, 2001 , 19(4) :1207 - 1225.
  • 4O'Reilly MS, Boehm T, Shing Y, et al. Endostatin : an endogenous inhibitor of angiogenesis and tumor growth [ J ]. Cell,1997, 88(2): 277 -285.
  • 5O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [J]. Cell, 1994,79 (2):315-328.
  • 6Jianhua Z, Feng Y, Huangxian J, et al. Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer [J]. Cancer Left, 2004, 204(1 ) :87 - 95.
  • 7Kuroi K, Tanaka C, Toi M, et al. Circulating levels of endostatin in cancer patients [J]. Oncol Reports, 2001, 8(2) : 405-409.
  • 8.
  • 9Hanahan D, Folkman J. Patterns and emerging mechanisms of the antigenic switch during tumorgenesis [J] . Cell, 1996 , 86 ( 2 ):353 - 364.
  • 10.

同被引文献9

  • 1吴唯,吕新生,唐中华,张翼,李小荣,陈道瑾.乳腺癌组织中VEGF mRNA的表达及其临床意义[J].中国普通外科杂志,2004,13(11):813-816. 被引量:5
  • 2Yu J,Bian D,Mahanivong C,et al.p38 Mitogen-activated protein kinase regulation of endothelial cell migration depends on urokinase plasminogen activator expression[J].J Biol Chem,2004,279(48):50446 -50454.
  • 3Dano K,Andreason PA,Grondahl-Hansen K,et al.Plasminogen activators,tissue degradation and cancer[J].Adv Cancer Res,1985,44(2):139 -266.
  • 4Neufeld G,Tessler S,Weindel K,et al.vascular permeability factor and its receptors[J].Prog Growth Factor Res,1994,5(1):89 -97.
  • 5Toi M,Hoshina S,Takayanagi T,et al.Association of vascular endothelial growth factor expression with tumor angiogensis and with early relapse in breast cancer[J].Jpn J Cancer Res,1994,85(10):1045-1049.
  • 6Manders P,Tjan-Heijnen VC,Span PN,et al.The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-Ⅰ) independently predicts response to first-line endocrine therapy in advanced breast cancer[J].Thromb Haemost.2004,91 (3):514 -521.
  • 7Duffy MJ.The urokinase plasminogen activator system:role in malignancy[J].Curr Pharm Des,2004,10 (1):39-49.
  • 8吴诚义,陈晋.nm23,整合素α_5β_1和VEGF在乳腺癌中的表达及其意义[J].中国普通外科杂志,2003,12(10):739-741. 被引量:1
  • 9肖继平,於席芳,徐翠琼,张莉,何赋容,王梅林,张广德,夏文华.腋淋巴结阴性乳腺癌uPA表达的临床意义[J].中华肿瘤杂志,2004,26(3):188-188. 被引量:19

引证文献1

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部